Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Salix

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,905 29 apr 2024 17:35
  • +0,005 (+0,56%) Dagrange 0,894 - 0,912
  • 4.531.435 Gem. (3M) 6,8M

Salix

42 Posts
Pagina: 1 2 3 »» | Laatste | Omlaag ↓
  1. sniper22 20 december 2013 10:55
    At Salix, we work hard every day to meet the current and anticipated needs of patients and healthcare providers. We are excited about the opportunity to drive this mission forward. On November 7, 2013 we announced our intention to purchase Santarus, Inc., a specialty biopharmaceutical company focused on providing gastroenterology products and other select specialties. Both Salix and Santarus share a commitment to integrity, ethics, teamwork, accountability and innovation. Through this acquisition, we will expand our ability to reach more patients and provide the additional products they need. We are excited to create a new company with greater scope and impact than either company could offer independently. This expansion is transformational for Salix, and I want to thank our employees and the employees at Santarus for their commitment and hard work that helped make this possible.

  6. sniper22 20 december 2013 11:24
    RALEIGH, NC, December 10, 2013—Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) ("Salix") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") in connection with Salix's proposed acquisition of Santarus, Inc. (NASDAQ:SNTS) ("Santarus") has expired.
    As previously announced, on December 3, 2013, Salix's indirect wholly owned subsidiary, Willow Acquisition Sub Corporation ("Purchaser"), initiated a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share, of Santarus at a purchase price of $32.00 per share, net to the seller in cash, without interest and subject to any required withholding taxes. The tender offer is being made in connection with the previously announced definitive merger agreement, dated as of November 7, 2013, among Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix ("Intermediary"), Purchaser and Santarus.
    The expiration of the HSR Act waiting period satisfies one of the conditions to the completion of the tender offer. Completion of the tender offer remains subject to other customary conditions as set forth in the Offer to Purchase filed by Purchaser, Salix and Intermediary with the U.S. Securities and Exchange Commission (the "SEC") on December 3, 2013, including the tender of at least a majority of the outstanding shares of common stock of Santarus on a fully diluted basis. The tender offer is scheduled to expire at 12:00 Midnight, New York City time, at the end of the day on December 31, 2013, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.

    Zolang de overname van santarus speelt zal er geen aktie te verwachten zijn rondom pharming...santarus heeft nu andere prioriteiten...koersvolume is al weken laag sinds het nieuws dat santarus overgenomen gaat worden!
  7. forum rang 10 DeZwarteRidder 20 december 2013 11:36
    quote:

    sniper22 schreef op 20 december 2013 11:24:

    Zolang de overname van santarus speelt zal er geen aktie te verwachten zijn rondom pharming...santarus heeft nu andere prioriteiten...koersvolume is al weken laag sinds het nieuws dat santarus overgenomen gaat worden!
    De kans is natuurlijk levensgroot, dat na de overname Pharming door de nieuwe baas wordt gedropt als hopeloos geval.......
  9. sniper22 20 december 2013 11:55
    About Pharming Group NV

    Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Santarus, Inc. (NASDAQ: SNTS) in North America and a BLA for RUCONEST was submitted to the FDA in April 2013. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell based technologies. Pharming now plans to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.

    Geduld
  10. [verwijderd] 20 december 2013 12:46
    quote:

    DeZwarteRidder schreef op 20 december 2013 11:36:

    [...]

    De kans is natuurlijk levensgroot, dat na de overname Pharming door de nieuwe baas wordt gedropt als hopeloos geval.......
    Wees blij man, dat er patienten zijn die baat hebben bij Ruconest/Rhucin!

    Enne dat hopeloosgeval ? Kijk eens in de spiegel !
  13. [verwijderd] 20 december 2013 13:38
    quote:

    DeZwarteRidder schreef op 20 december 2013 13:14:

    kippekop 5 jan 2011 om 11:02

    Let maar op ,alle positieve zaken op een rijtje genomen moet het dit jaar gaan verbeteren.

    Jammer voor de negatieven onder ons

    Dus niet....!!
    Daar heb je een punt, in die periode stond Pharming boven de € 0.20.

    Misschien komend jaar ?
  16. [verwijderd] 20 december 2013 13:59
    quote:

    sniper22 schreef op 20 december 2013 13:43:

    Waarom zou salix een middel met potentie zo kort voor mogelijke goedkeuring de deur uitdoen?. Verwacht eerder dat salix pharming zal overnemen in de periode februari/ maart 2014...krijgt sijmen een mooie bonus!
    Waarom zou je in vredesnaam een zinkend schip overnemen?
  18. [verwijderd] 20 december 2013 16:44

    Gewoon vasthouden, komt vanzelf goed. Wachten is op FDA.
    Dan krijgt men weer interesse en gaat de koers koers naar € 0.60.
    Je ziet ook aan het verhandelde volume van de laatste tijd, dat er maar weinig mensen zijn die ze wegdoen.
    En wat mijzelf betreft......verlies lijd ik pas onder € 0.124.
    Komt de koers daar voor 16 april onder, koop ik weer wat bij.
    Na 16 april komen we niet meer onder de €0.35 !

    Groetjes en allen een prettig weekend :-)
  19. sniper22 3 januari 2014 20:56
    RALEIGH, NC, January 2, 2014 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc., (NASDAQ:SNTS), at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Following the tender offer, Salix completed the acquisition of Santarus earlier today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.

    "The acquisition of Santarus is a transformational event for Salix and an important milestone in our growth as the leading gastroenterology-focused specialty pharmaceutical company in the United States," stated Carolyn Logan, Salix President and Chief Executive Officer. "The creation of a larger, stronger Salix reinforces our premier position in gastroenterology and creates the opportunity for us to expand our digestive disease expertise into other key specialties."

    "Beginning today," continued Ms. Logan, "We are positioned to continue the growth of our business with an expanded portfolio of products and an expanded sales effort. Our product portfolio now offers 22 marketed products, including: XIFAXAN®, UCERIS®, GLUMETZA®, APRISO®, ZEGERID®, MOVIPREP®, RELISTOR®, SOLESTA®, FULYZAQ®, CYCLOSET® and DEFLUX®. And, going forward, our sales effort will benefit from the addition of a new 100-member gastrointestinal-focused sales force and the creation of a new, 160-member digestive disease specialty sales force. The new GI sales force will complement the efforts of our current 200-member GI sales force and provide greater reach and frequency for our products with gastroenterologists, hepatologists and colorectal surgeons. The new digestive disease specialty sales force will expand our specialty sales effort to target endocrinologists, infectious disease, pain specialists and high volume primary care physicians – prescribers formerly not accessed by our GI-focused sales effort. This expansion of our sales effort into these specialties represents an exciting area of growth for Salix. We believe these strategic additions to our sales effort should increase sales of our current products in the short term and begin to position the Company to maximize the sales of potential products over the longer term."

    As of the expiration of the tender offer, 54,558,962 shares of common stock of Santarus (including 1,998,716 shares subject to notices of guaranteed delivery) were validly tendered and not validly withdrawn in the tender offer, representing 79.3% of the outstanding shares, according to the depositary for the tender offer. All validly tendered shares have been accepted for payment, and payment for such shares will be made promptly.

    In the merger, each share of common stock of Santarus not tendered in the tender offer (other than shares held by Salix, Salix Pharmaceuticals, Inc., Willow Acquisition Sub Corporation and Santarus, and other than shares held by a holder who has properly demanded and perfected appraisal rights in accordance with Section 262 of Delaware General Corporation Law) was converted into the right to receive $32.00 per share in cash, without interest and less any applicable withholding taxes thereon. This is the same price per share paid in the tender offer. Salix financed the tender offer and merger through a combination of (i) a term loan facility in the amount of $1.2 billion (ii) $750 million of 6.000% Senior Notes due 2021 and (iii) cash on hand. In connection with the merger, Santarus' shares have ceased to be traded on the NASDAQ Global Market and the NASDAQ has filed a Form 25 with the U.S. Securities and Exchange Commission (the "SEC").

    About Salix

    Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through Salix's gastroenterology specialty sales and marketing team.

    Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP".
42 Posts
Pagina: 1 2 3 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Logische herfinanciering Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  2. 18 apr Pharming rondt plaatsing obligaties af 5
  3. 18 apr Pharming vervangt converteerbare lening 6
  4. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  5. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  6. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?
  7. 14 mrt Pharming rekent ook voor 2024 op dubbelcijferige omzetgroei 2
  8. 13 mrt Slotcall: Twijfel slaat toe bij chippers, AEX sluit iets lager na wispelturige sessie
  9. 11 mrt Beursblik: hogere jaaromzet Pharming verwacht
  10. 11 mrt AEX gaat opnieuw rode opening tegemoet, Japan ontloopt recessie maar Nikkei duikelt 1

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!